Skip to content

Learning to attend to pain

Learning to attend to pain - Learning to attend to pain

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON38878
Enrollment
48
Registered
2013-11-06
Start date
2014-02-04
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

None listed

Sponsors

Universiteit Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All participants will be healthy and pain-free as determined by self-report, between 18 and 75 years of age, and capable of speaking and reading Dutch.

Exclusion criteria

Exclusion criteria: Participants will be excluded when they use psychotropic or analgesic drugs (e.g., opioids such as morphine or tramadol, tricyclic antidepressants such as amitriptyline or nortriptyline, anticonvulsants such as gabapentin or carbamazepine, or antipsychotics such as haloperidol) that affect reaction times or pain perception, or when participants are allergic for Spanish peppers or have psoriasis on one of their hands.

Design outcomes

Primary

MeasureTime frame
Reaction time (RT) to targets in a visual search task. When an irrelevant distractor is presented during the visual search, attention is captured and response times become longer as compared to no-distractor present trials. This RT effect is expected to vary according to the presence and the spatial position of the painful hand.

Secondary

MeasureTime frame
Detection accuracy, *learnability*; the speed (number of trials necessary) at which a participant learns and *unlearns* a new association between two events; number of trials that are required to learn a new association, saccade latency; delay in response times of eye movements, saccade accuracy; eye movement in the correct direction.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)